| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 43 | 2024 | 512 | 8.370 |
Why?
|
| Adenomatous Polyposis Coli | 17 | 2022 | 28 | 4.410 |
Why?
|
| Stomach Neoplasms | 9 | 2025 | 241 | 3.850 |
Why?
|
| Adenoma | 17 | 2023 | 96 | 3.620 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 11 | 2026 | 19 | 3.510 |
Why?
|
| Adenocarcinoma | 10 | 2025 | 291 | 3.050 |
Why?
|
| Colonic Polyps | 9 | 2023 | 71 | 2.210 |
Why?
|
| Genetic Testing | 9 | 2025 | 91 | 2.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2025 | 220 | 1.970 |
Why?
|
| Puerto Rico | 25 | 2025 | 1413 | 1.950 |
Why?
|
| Mutation | 11 | 2025 | 1177 | 1.940 |
Why?
|
| Colonoscopy | 16 | 2023 | 122 | 1.440 |
Why?
|
| Middle Aged | 70 | 2026 | 12222 | 1.430 |
Why?
|
| Humans | 112 | 2026 | 43102 | 1.410 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2024 | 56 | 1.340 |
Why?
|
| Aged | 54 | 2026 | 8214 | 1.320 |
Why?
|
| Early Detection of Cancer | 9 | 2025 | 449 | 1.270 |
Why?
|
| Helicobacter Infections | 5 | 2024 | 86 | 1.230 |
Why?
|
| Female | 81 | 2026 | 24698 | 1.230 |
Why?
|
| Colonic Neoplasms | 6 | 2023 | 223 | 1.210 |
Why?
|
| Male | 76 | 2026 | 23409 | 1.210 |
Why?
|
| Genetic Predisposition to Disease | 12 | 2024 | 734 | 1.160 |
Why?
|
| Carcinoma | 4 | 2017 | 108 | 0.990 |
Why?
|
| DNA Mismatch Repair | 4 | 2020 | 28 | 0.970 |
Why?
|
| MutS Homolog 2 Protein | 6 | 2019 | 32 | 0.950 |
Why?
|
| Mass Screening | 6 | 2025 | 541 | 0.940 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2019 | 989 | 0.940 |
Why?
|
| Esophagogastric Junction | 1 | 2025 | 8 | 0.930 |
Why?
|
| Esophageal Neoplasms | 2 | 2025 | 140 | 0.910 |
Why?
|
| Helicobacter pylori | 5 | 2024 | 118 | 0.860 |
Why?
|
| Adult | 49 | 2026 | 13872 | 0.840 |
Why?
|
| Curcumin | 4 | 2024 | 118 | 0.830 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 24 | 0.780 |
Why?
|
| Advisory Committees | 2 | 2020 | 35 | 0.750 |
Why?
|
| Precancerous Conditions | 6 | 2024 | 83 | 0.720 |
Why?
|
| Neoplasms | 8 | 2025 | 1377 | 0.720 |
Why?
|
| Occult Blood | 4 | 2016 | 32 | 0.710 |
Why?
|
| Insulin-Like Growth Factor II | 5 | 2011 | 25 | 0.700 |
Why?
|
| DNA-Binding Proteins | 5 | 2025 | 561 | 0.690 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2018 | 10 | 0.650 |
Why?
|
| Colectomy | 3 | 2018 | 24 | 0.650 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 495 | 0.640 |
Why?
|
| Genomic Imprinting | 4 | 2011 | 35 | 0.640 |
Why?
|
| Antineoplastic Agents | 4 | 2025 | 1019 | 0.630 |
Why?
|
| Career Choice | 2 | 2017 | 52 | 0.590 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 223 | 0.590 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2015 | 213 | 0.580 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 83 | 0.580 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 88 | 0.570 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2022 | 23 | 0.570 |
Why?
|
| Gastritis, Atrophic | 2 | 2024 | 13 | 0.560 |
Why?
|
| Gastroenterology | 3 | 2017 | 8 | 0.560 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 14 | 0.550 |
Why?
|
| Immunoglobulin G | 2 | 2023 | 259 | 0.540 |
Why?
|
| Microsatellite Instability | 4 | 2026 | 48 | 0.530 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 117 | 0.530 |
Why?
|
| Aged, 80 and over | 21 | 2024 | 2853 | 0.520 |
Why?
|
| Career Mobility | 1 | 2017 | 29 | 0.500 |
Why?
|
| Prevalence | 11 | 2023 | 1612 | 0.500 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2016 | 20 | 0.500 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2008 | 146 | 0.500 |
Why?
|
| Nuclear Proteins | 4 | 2015 | 333 | 0.490 |
Why?
|
| Health Education | 1 | 2019 | 363 | 0.480 |
Why?
|
| Public Health | 1 | 2020 | 424 | 0.470 |
Why?
|
| Occupational Exposure | 1 | 2016 | 91 | 0.470 |
Why?
|
| Risk Factors | 13 | 2018 | 3994 | 0.470 |
Why?
|
| Biomedical Research | 4 | 2019 | 502 | 0.470 |
Why?
|
| Case-Control Studies | 8 | 2024 | 1285 | 0.470 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 50 | 0.460 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 9 | 0.460 |
Why?
|
| Digestive System Neoplasms | 1 | 2014 | 4 | 0.440 |
Why?
|
| Adenomatous Polyps | 3 | 2015 | 13 | 0.440 |
Why?
|
| Double-Blind Method | 5 | 2025 | 317 | 0.430 |
Why?
|
| Dietary Supplements | 3 | 2017 | 213 | 0.430 |
Why?
|
| DNA Glycosylases | 1 | 2013 | 17 | 0.410 |
Why?
|
| Interprofessional Relations | 1 | 2013 | 59 | 0.400 |
Why?
|
| Retrospective Studies | 12 | 2025 | 2544 | 0.390 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 1067 | 0.390 |
Why?
|
| Cross-Sectional Studies | 8 | 2020 | 3156 | 0.380 |
Why?
|
| Mentors | 1 | 2013 | 145 | 0.370 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2025 | 163 | 0.370 |
Why?
|
| Barrett Esophagus | 4 | 2014 | 29 | 0.350 |
Why?
|
| Physicians | 1 | 2013 | 188 | 0.350 |
Why?
|
| Liver Neoplasms | 2 | 2025 | 224 | 0.350 |
Why?
|
| Smoking | 3 | 2016 | 1024 | 0.350 |
Why?
|
| Registries | 7 | 2019 | 437 | 0.350 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2009 | 31 | 0.350 |
Why?
|
| Biopsy | 3 | 2014 | 177 | 0.340 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 590 | 0.340 |
Why?
|
| Vitamins | 2 | 2015 | 81 | 0.340 |
Why?
|
| Endometrial Neoplasms | 1 | 2012 | 79 | 0.340 |
Why?
|
| DNA Methylation | 3 | 2023 | 403 | 0.320 |
Why?
|
| Calcium, Dietary | 1 | 2010 | 65 | 0.320 |
Why?
|
| Prognosis | 4 | 2018 | 861 | 0.300 |
Why?
|
| Barium Sulfate | 1 | 2009 | 2 | 0.300 |
Why?
|
| Enema | 1 | 2009 | 10 | 0.300 |
Why?
|
| Young Adult | 11 | 2019 | 5080 | 0.300 |
Why?
|
| Contrast Media | 2 | 2009 | 103 | 0.300 |
Why?
|
| Quercetin | 2 | 2006 | 46 | 0.300 |
Why?
|
| United States | 9 | 2022 | 5205 | 0.290 |
Why?
|
| Treatment Outcome | 8 | 2024 | 1604 | 0.290 |
Why?
|
| Obesity | 1 | 2016 | 1151 | 0.280 |
Why?
|
| Placebos | 3 | 2025 | 41 | 0.270 |
Why?
|
| Duodenal Neoplasms | 2 | 2022 | 4 | 0.270 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2007 | 13 | 0.260 |
Why?
|
| Colon | 4 | 2017 | 120 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 760 | 0.250 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 440 | 0.250 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2006 | 1 | 0.250 |
Why?
|
| Enteral Nutrition | 1 | 2006 | 17 | 0.240 |
Why?
|
| Hormone Replacement Therapy | 1 | 2006 | 49 | 0.240 |
Why?
|
| Cancer Vaccines | 1 | 2026 | 30 | 0.240 |
Why?
|
| Gene Rearrangement | 1 | 2025 | 17 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2025 | 9 | 0.230 |
Why?
|
| Phenylurea Compounds | 1 | 2025 | 18 | 0.230 |
Why?
|
| Catechin | 1 | 2025 | 39 | 0.230 |
Why?
|
| Antigens, Neoplasm | 1 | 2026 | 90 | 0.230 |
Why?
|
| Antigens, CD | 1 | 2025 | 127 | 0.220 |
Why?
|
| Liver Cirrhosis | 1 | 2025 | 67 | 0.220 |
Why?
|
| Proton Pump Inhibitors | 2 | 2016 | 16 | 0.220 |
Why?
|
| Cadherins | 1 | 2025 | 102 | 0.220 |
Why?
|
| Genome-Wide Association Study | 2 | 2024 | 423 | 0.220 |
Why?
|
| Time Factors | 7 | 2020 | 1857 | 0.220 |
Why?
|
| Minority Groups | 2 | 2020 | 690 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2025 | 159 | 0.210 |
Why?
|
| Quantitative Trait Loci | 1 | 2024 | 88 | 0.210 |
Why?
|
| Risk Assessment | 5 | 2018 | 863 | 0.200 |
Why?
|
| Adolescent | 9 | 2018 | 6081 | 0.200 |
Why?
|
| Neoplasm Proteins | 1 | 2025 | 228 | 0.200 |
Why?
|
| Age Factors | 4 | 2017 | 1154 | 0.200 |
Why?
|
| Sensitivity and Specificity | 4 | 2009 | 611 | 0.200 |
Why?
|
| Germ-Line Mutation | 3 | 2025 | 75 | 0.200 |
Why?
|
| Gene Amplification | 1 | 2023 | 23 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2025 | 220 | 0.200 |
Why?
|
| Vaccines, DNA | 1 | 2023 | 24 | 0.200 |
Why?
|
| Muir-Torre Syndrome | 2 | 2015 | 2 | 0.190 |
Why?
|
| Incidence | 4 | 2022 | 1078 | 0.190 |
Why?
|
| Hepatitis C, Chronic | 1 | 2023 | 44 | 0.190 |
Why?
|
| Antioxidants | 1 | 2006 | 443 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2024 | 863 | 0.190 |
Why?
|
| Proteins | 1 | 2005 | 382 | 0.190 |
Why?
|
| Liver | 1 | 2025 | 511 | 0.180 |
Why?
|
| Sulindac | 1 | 2002 | 9 | 0.180 |
Why?
|
| Latin America | 2 | 2025 | 55 | 0.180 |
Why?
|
| Sex Factors | 3 | 2017 | 1028 | 0.180 |
Why?
|
| Disease Progression | 5 | 2017 | 667 | 0.180 |
Why?
|
| Cost of Illness | 2 | 2014 | 98 | 0.180 |
Why?
|
| Hepatitis C | 1 | 2023 | 139 | 0.180 |
Why?
|
| Tumor Burden | 2 | 2018 | 84 | 0.170 |
Why?
|
| Prospective Studies | 6 | 2024 | 1600 | 0.170 |
Why?
|
| Pedigree | 2 | 2018 | 94 | 0.170 |
Why?
|
| Calcium | 3 | 2017 | 491 | 0.160 |
Why?
|
| Transcription Factors | 1 | 2025 | 735 | 0.160 |
Why?
|
| Quality of Life | 1 | 2025 | 616 | 0.160 |
Why?
|
| GTP Phosphohydrolases | 1 | 2020 | 34 | 0.160 |
Why?
|
| Immunohistochemistry | 2 | 2020 | 934 | 0.160 |
Why?
|
| Patient Selection | 2 | 2018 | 205 | 0.150 |
Why?
|
| Metaplasia | 2 | 2016 | 39 | 0.150 |
Why?
|
| Cholecystitis | 3 | 2003 | 7 | 0.150 |
Why?
|
| Indians, Central American | 1 | 2019 | 3 | 0.150 |
Why?
|
| Heredity | 1 | 2018 | 7 | 0.150 |
Why?
|
| Behavioral Research | 1 | 2019 | 41 | 0.140 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2010 | 88 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 15 | 0.140 |
Why?
|
| Minority Health | 1 | 2019 | 95 | 0.140 |
Why?
|
| Schools, Medical | 1 | 2020 | 208 | 0.140 |
Why?
|
| Drug Therapy, Combination | 4 | 2016 | 234 | 0.140 |
Why?
|
| Socioeconomic Factors | 3 | 2017 | 1234 | 0.140 |
Why?
|
| Intestinal Polyps | 2 | 2010 | 4 | 0.140 |
Why?
|
| Health Care Costs | 1 | 2018 | 91 | 0.140 |
Why?
|
| Seroepidemiologic Studies | 1 | 2017 | 74 | 0.140 |
Why?
|
| Alcohol Drinking | 3 | 2016 | 609 | 0.130 |
Why?
|
| Obesity, Morbid | 2 | 2008 | 30 | 0.130 |
Why?
|
| Esophagus | 2 | 2014 | 42 | 0.130 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 374 | 0.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 67 | 0.130 |
Why?
|
| DNA Repair Enzymes | 1 | 2017 | 22 | 0.130 |
Why?
|
| Amoxicillin | 1 | 2016 | 2 | 0.130 |
Why?
|
| Clarithromycin | 1 | 2016 | 9 | 0.130 |
Why?
|
| Vitamin D | 2 | 2017 | 196 | 0.130 |
Why?
|
| Workload | 1 | 2017 | 25 | 0.130 |
Why?
|
| Metronidazole | 1 | 2016 | 16 | 0.130 |
Why?
|
| Gastrectomy | 1 | 2016 | 13 | 0.130 |
Why?
|
| Insurance, Health | 2 | 2016 | 145 | 0.130 |
Why?
|
| Health Status Disparities | 2 | 2020 | 719 | 0.130 |
Why?
|
| Health Planning | 1 | 2016 | 16 | 0.130 |
Why?
|
| Insurance Coverage | 2 | 2014 | 110 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 76 | 0.120 |
Why?
|
| Membrane Proteins | 1 | 2020 | 561 | 0.120 |
Why?
|
| Government Programs | 1 | 2016 | 29 | 0.120 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 38 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2016 | 224 | 0.120 |
Why?
|
| Sigmoidoscopy | 3 | 2016 | 9 | 0.120 |
Why?
|
| Hospitals, University | 1 | 2015 | 39 | 0.120 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2015 | 18 | 0.120 |
Why?
|
| Caribbean Region | 1 | 2015 | 79 | 0.120 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2006 | 9 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 218 | 0.110 |
Why?
|
| Phenotype | 3 | 2013 | 780 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2016 | 144 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2025 | 375 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 306 | 0.110 |
Why?
|
| Feces | 1 | 2015 | 132 | 0.110 |
Why?
|
| Rural Population | 1 | 2017 | 373 | 0.110 |
Why?
|
| Decision Making | 1 | 2016 | 249 | 0.100 |
Why?
|
| Odds Ratio | 5 | 2017 | 587 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 652 | 0.100 |
Why?
|
| Polyps | 2 | 2004 | 9 | 0.100 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2003 | 3 | 0.100 |
Why?
|
| Syndrome | 1 | 2013 | 73 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 638 | 0.100 |
Why?
|
| Metformin | 1 | 2014 | 75 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 432 | 0.100 |
Why?
|
| Genotype | 2 | 2013 | 800 | 0.100 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2012 | 28 | 0.090 |
Why?
|
| Dinoprostone | 1 | 2012 | 64 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 114 | 0.090 |
Why?
|
| Family | 1 | 2013 | 195 | 0.090 |
Why?
|
| Radiography | 2 | 2009 | 71 | 0.090 |
Why?
|
| Aspirin | 1 | 2012 | 89 | 0.090 |
Why?
|
| Mouth Mucosa | 1 | 2011 | 30 | 0.090 |
Why?
|
| DNA Mutational Analysis | 3 | 2020 | 95 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 165 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2011 | 183 | 0.080 |
Why?
|
| Diet Records | 1 | 2010 | 58 | 0.080 |
Why?
|
| ras Proteins | 1 | 2010 | 54 | 0.080 |
Why?
|
| Public Policy | 1 | 2010 | 36 | 0.080 |
Why?
|
| Recurrence | 2 | 2012 | 152 | 0.080 |
Why?
|
| Diet | 1 | 2016 | 826 | 0.080 |
Why?
|
| Lymphocytes | 3 | 2011 | 124 | 0.080 |
Why?
|
| Child | 4 | 2013 | 3443 | 0.080 |
Why?
|
| North America | 2 | 2017 | 85 | 0.080 |
Why?
|
| Cholelithiasis | 3 | 2003 | 5 | 0.080 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2008 | 1 | 0.070 |
Why?
|
| Rectal Neoplasms | 1 | 2009 | 20 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2015 | 518 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 238 | 0.070 |
Why?
|
| Genomic Instability | 1 | 2009 | 37 | 0.070 |
Why?
|
| Duodenoscopy | 2 | 2010 | 2 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2009 | 74 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2010 | 257 | 0.070 |
Why?
|
| DNA Repair | 1 | 2010 | 198 | 0.070 |
Why?
|
| Bariatric Surgery | 1 | 2008 | 23 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 497 | 0.070 |
Why?
|
| Mesalamine | 1 | 2008 | 2 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1455 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2012 | 925 | 0.070 |
Why?
|
| Gastric Fundus | 2 | 2004 | 3 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 458 | 0.070 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2007 | 9 | 0.070 |
Why?
|
| Antibodies, Fungal | 1 | 2007 | 24 | 0.060 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2006 | 1 | 0.060 |
Why?
|
| Mitochondria | 1 | 2010 | 523 | 0.060 |
Why?
|
| Gastric Bypass | 1 | 2006 | 22 | 0.060 |
Why?
|
| Jejunostomy | 1 | 2006 | 2 | 0.060 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2008 | 104 | 0.060 |
Why?
|
| Bile Duct Diseases | 1 | 2006 | 2 | 0.060 |
Why?
|
| Crohn Disease | 1 | 2007 | 71 | 0.060 |
Why?
|
| Vaccinia virus | 1 | 2026 | 13 | 0.060 |
Why?
|
| Epigenesis, Genetic | 1 | 2009 | 291 | 0.060 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2007 | 199 | 0.060 |
Why?
|
| Anilides | 1 | 2025 | 28 | 0.060 |
Why?
|
| Contraceptives, Oral | 1 | 2005 | 17 | 0.060 |
Why?
|
| Phytotherapy | 1 | 2005 | 75 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2025 | 17 | 0.060 |
Why?
|
| Honduras | 1 | 2024 | 8 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 968 | 0.060 |
Why?
|
| Chemoprevention | 1 | 2024 | 41 | 0.060 |
Why?
|
| Quinolines | 1 | 2025 | 78 | 0.050 |
Why?
|
| Guideline Adherence | 2 | 2017 | 98 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2005 | 101 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2006 | 263 | 0.050 |
Why?
|
| Education, Medical | 1 | 2006 | 118 | 0.050 |
Why?
|
| Acetonitriles | 1 | 2024 | 10 | 0.050 |
Why?
|
| CpG Islands | 1 | 2004 | 109 | 0.050 |
Why?
|
| Cohort Studies | 4 | 2015 | 1759 | 0.050 |
Why?
|
| Duodenal Diseases | 1 | 2003 | 3 | 0.050 |
Why?
|
| Dietary Fiber | 1 | 2004 | 51 | 0.050 |
Why?
|
| Sphincter of Oddi | 1 | 2003 | 2 | 0.050 |
Why?
|
| Folic Acid | 1 | 2004 | 49 | 0.050 |
Why?
|
| Nitroprusside | 1 | 2003 | 14 | 0.050 |
Why?
|
| Gastrointestinal Motility | 1 | 2003 | 20 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2024 | 199 | 0.050 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2003 | 25 | 0.050 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 26 | 0.050 |
Why?
|
| Nitric Oxide Donors | 1 | 2003 | 41 | 0.050 |
Why?
|
| Piperazines | 1 | 2024 | 120 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2004 | 117 | 0.050 |
Why?
|
| Mucin-1 | 1 | 2023 | 12 | 0.050 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2003 | 2 | 0.050 |
Why?
|
| Curriculum | 1 | 2006 | 318 | 0.050 |
Why?
|
| Vaccines, Subunit | 1 | 2023 | 34 | 0.050 |
Why?
|
| Cryotherapy | 1 | 2003 | 11 | 0.050 |
Why?
|
| Cholecystectomy | 1 | 2003 | 14 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2024 | 139 | 0.050 |
Why?
|
| Pancreatitis | 1 | 2003 | 21 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2023 | 46 | 0.050 |
Why?
|
| Pancreas | 1 | 2003 | 45 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2024 | 237 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2023 | 74 | 0.050 |
Why?
|
| Duodenum | 1 | 2022 | 15 | 0.050 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2023 | 53 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2025 | 1124 | 0.050 |
Why?
|
| Remission Induction | 2 | 2016 | 19 | 0.050 |
Why?
|
| Rectum | 1 | 2002 | 27 | 0.050 |
Why?
|
| Risk | 2 | 2015 | 287 | 0.050 |
Why?
|
| Plasmids | 1 | 2023 | 244 | 0.050 |
Why?
|
| Selenium | 1 | 2004 | 155 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2002 | 34 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2002 | 116 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2004 | 256 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 116 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2002 | 192 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 154 | 0.040 |
Why?
|
| DNA | 1 | 2023 | 592 | 0.040 |
Why?
|
| South America | 1 | 2019 | 24 | 0.040 |
Why?
|
| HCT116 Cells | 2 | 2010 | 40 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 89 | 0.040 |
Why?
|
| Fanconi Anemia Complementation Group F Protein | 1 | 2018 | 1 | 0.040 |
Why?
|
| Fanconi Anemia | 1 | 2018 | 8 | 0.040 |
Why?
|
| Gastric Mucosa | 2 | 2011 | 65 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2018 | 50 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2018 | 48 | 0.030 |
Why?
|
| Maryland | 2 | 2008 | 66 | 0.030 |
Why?
|
| Research Personnel | 1 | 2019 | 206 | 0.030 |
Why?
|
| Cultural Diversity | 1 | 2019 | 193 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 107 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 2017 | 77 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2016 | 50 | 0.030 |
Why?
|
| District of Columbia | 1 | 2015 | 80 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 60 | 0.030 |
Why?
|
| Chronic Disease | 3 | 2003 | 549 | 0.030 |
Why?
|
| Urban Health | 1 | 2015 | 101 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 240 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 236 | 0.030 |
Why?
|
| Endoscopy, Digestive System | 1 | 2014 | 7 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2014 | 9 | 0.030 |
Why?
|
| Health Care Reform | 1 | 2014 | 36 | 0.030 |
Why?
|
| Animals | 3 | 2025 | 16992 | 0.030 |
Why?
|
| Habits | 1 | 2013 | 8 | 0.030 |
Why?
|
| Survival Rate | 1 | 2014 | 355 | 0.020 |
Why?
|
| Intestinal Mucosa | 2 | 2005 | 134 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2013 | 152 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1009 | 0.020 |
Why?
|
| Esophagoscopy | 1 | 2012 | 7 | 0.020 |
Why?
|
| Insulin | 1 | 2014 | 258 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2010 | 2676 | 0.020 |
Why?
|
| Educational Status | 1 | 2013 | 339 | 0.020 |
Why?
|
| Medicare | 1 | 2014 | 332 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2010 | 39 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 110 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 456 | 0.020 |
Why?
|
| Anemia | 1 | 2010 | 55 | 0.020 |
Why?
|
| Health Promotion | 1 | 2016 | 704 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 186 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2003 | 760 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2010 | 206 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 25 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 23 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 81 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2009 | 47 | 0.020 |
Why?
|
| Colon, Descending | 1 | 2008 | 2 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 706 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2009 | 63 | 0.020 |
Why?
|
| Veterans | 1 | 2010 | 210 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 883 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2008 | 62 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2008 | 60 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 60 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 737 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2008 | 42 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 532 | 0.020 |
Why?
|
| Diatrizoate Meglumine | 1 | 2006 | 2 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 139 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 704 | 0.020 |
Why?
|
| Florida | 1 | 2008 | 478 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 347 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2005 | 7 | 0.020 |
Why?
|
| Antilymphocyte Serum | 1 | 2005 | 4 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 263 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2005 | 32 | 0.010 |
Why?
|
| Cadaver | 1 | 2005 | 40 | 0.010 |
Why?
|
| Heme Oxygenase-1 | 1 | 2005 | 52 | 0.010 |
Why?
|
| Alleles | 1 | 2007 | 352 | 0.010 |
Why?
|
| Linear Models | 1 | 2006 | 317 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2006 | 135 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2005 | 53 | 0.010 |
Why?
|
| Menstruation Disturbances | 1 | 2005 | 2 | 0.010 |
Why?
|
| Prostaglandins | 1 | 2005 | 23 | 0.010 |
Why?
|
| Genes, p16 | 1 | 2004 | 11 | 0.010 |
Why?
|
| Flavonoids | 1 | 2005 | 100 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2006 | 156 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 539 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 294 | 0.010 |
Why?
|
| Manometry | 1 | 2003 | 8 | 0.010 |
Why?
|
| Digestive System Diseases | 1 | 2003 | 4 | 0.010 |
Why?
|
| Injections | 1 | 2003 | 42 | 0.010 |
Why?
|
| Cholestasis | 1 | 2003 | 12 | 0.010 |
Why?
|
| Sclerosis | 1 | 2003 | 5 | 0.010 |
Why?
|
| Gastric Antral Vascular Ectasia | 1 | 2003 | 1 | 0.010 |
Why?
|
| Pancreatic Diseases | 1 | 2003 | 6 | 0.010 |
Why?
|
| Proctitis | 1 | 2003 | 2 | 0.010 |
Why?
|
| Arteriovenous Malformations | 1 | 2003 | 2 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 455 | 0.010 |
Why?
|
| Gastritis | 1 | 2003 | 13 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2003 | 23 | 0.010 |
Why?
|
| Swine | 1 | 2003 | 212 | 0.010 |
Why?
|
| Family Health | 1 | 2003 | 55 | 0.010 |
Why?
|
| Genes, APC | 1 | 2002 | 15 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2003 | 259 | 0.010 |
Why?
|
| Point Mutation | 1 | 2002 | 98 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2002 | 162 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 82 | 0.010 |
Why?
|
| beta Catenin | 1 | 2002 | 78 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2002 | 179 | 0.010 |
Why?
|
| California | 1 | 2002 | 548 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2002 | 719 | 0.010 |
Why?
|
| Aging | 1 | 2003 | 783 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 6644 | 0.010 |
Why?
|